Bethesda, MDNCT02147405Now EnrollingIRB Ready

Immune Reconstitution Inflammatory Syndrome Clinical Trial in Bethesda, MD

Access cutting-edge immune reconstitution inflammatory syndrome treatment through this clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

Quick Self-Assessment

See if you qualify for this Bethesda location

Preparing your pre-screening questions…

Expert Care in Bethesda

Access immune reconstitution inflammatory syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related immune reconstitution inflammatory syndrome treatment provided free

Apply for This Bethesda Location

Check if you qualify for this immune reconstitution inflammatory syndrome clinical trial in Bethesda, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Bethesda

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Bethesda site if eligible
  4. 4Begin participation

About This Immune Reconstitution Inflammatory Syndrome Study in Bethesda

Background: \- Sometimes people with HIV, the virus that causes AIDS, can have new or worsening symptoms soon after starting HIV medications. Often these symptoms are caused by immune reconstitution inflammatory syndrome (IRIS). Researchers want to study why and how people develop IRIS and how best to prevent and treat it. Objectives: \- To learn the causes and effects of IRIS, and how to best manage it. Eligibility: \- Adults 18 and older with HIV and low CD4 counts,, about to start HIV medicines; or those already taking HIV medicines with symptoms thought to be related to IRIS. Design: * Participants not on ART will have screening blood tests for CD4 count, HIV viral load and genetic testing. * After the screening blood tests and before starting HIV medicines., participants will return for more than 1 visit for the following: * review of medical history\<TAB\> * physical and eye exams * blood, urine, and tuberculosis (TB) tests * electrocardiogram (EKG) * chest x-ray * apheresis: a blood drawing procedure where blood is removed from a vein, white blood cells are separated and collected, and the rest of the blood is returned to the person using another vein * \- PET scan - a procedure where a small amount of radioactive material is injected in a vein. The participant then lies on a table that slides into a scanner which takes images of the body. * lymph node biopsy * stool collection by swab * After completion of the above, HIV medicines will be started. * Follow-up visits will be at 2, 4, 8, and 12 weeks after starting ART, then every 12 weeks. Some of the tests above may be repeated. * Participants already on HIV medicines who may have IRIS will be screened over a 4 week time period to see if they really are experiencing IRIS. The screening process will include all of the items listed above. Follow-up visits will be at Weeks, 4, 8, 12 and then every 12 weeks. * The study will last 1 year for both groups but may be extended to 2 years (3 additional appointments) for some participants.

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Who Can Participate

Inclusion Criteria

Documentation of HIV-1 infection. Results from outside facilities will be accepted for enrollment.
No recent (within the past two years) treatment with combination anti-retroviral therapy (ART). Patients with limited (no more than 2-3 weeks) recent use of potent combination ART may be eligible for study participation if, the opinion of the investigator, the ART usage will not impact the scientific validity of the protocol
Documented CD4+ cell count \<=100 cells/mm\^3 within the past 8 weeks.
Residence within the wider Washington D.C. area (within a 100-mile radius from the NIH Bethesda campus) and plans to stay in the area for 48 weeks
Men or women age \>=18 years.
Ability and willingness of subject (or legal guardian/representative) to understand study requirements and give informed consent\*.
Willingness to allow storage of blood or tissue samples for future research
Willingness at time of screening to undergo study procedures (phlebotomy, apheresis, optional FDG-PET/CT and lymph node biopsy)
Willingness to have genetic testing
Participants should have a primary care physician or will need to agree to have one established by 24 weeks on study.
Potential participants who lack decision-making capacity to consent to research participation may enroll in this study at the discretion of the investigator if this incapacity is expected to last for a short period of time. IRIS ARM INCLUSION CRITERIA:
Documentation of HIV-1 infection. Results from outside facilities will be accepted for enrollment.
Meet criteria suspicious for IRIS (Must meet 4/5 following criteria):
Initiation (reintroduction or change) in antiretroviral therapy/regimen
Evidence of: i. an increase in CD4+ cell count defined as \>= 50cell/mm\^3 or a \>= 2 fold rise in CD4+ cell count, and/or ii. decrease in the HIV-1 viral load of \>=0.5 log10 c. Symptoms and/or signs consistent with an infectious/inflammatory condition. d. These symptoms and/or signs cannot be explained by a newly acquired infection, the expected clinical course of a previously recognized infectious agent, or the side effects of antiretroviral therapy itself. e. The infectious/inflammatory condition must be attributable to a specific pathogen or condition. Criteria d or e may not be met for suspected IRIS definition.
Residence within the wider Washington D.C. area (within a 100-mile radius from the NIH Bethesda campus) \*\*Participants from outside of the 100 mile radius may be enrolled on a case by case basis to diagnose or manage IRIS.
Men or women age \>=18 years.
Ability and willingness of subject to understand study requirements and give informed consent\*.
Willingness to allow storage of blood or tissue samples for future research
Willingness at time of screening to undergo study procedures (phlebotomy, apheresis, an optional FDG-PET/CT, and lymph node biopsy)
Willingness to have genetic testing
Participants should have a primary care physician who will initiate the referral.
Potential participants who lack decision-making capacity to consent to research participation may enroll in this study at the discretion of the investigator if this incapacity is expected to last for a short period of time. SUBJECT

Exclusion Criteria

Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
Pregnancy will be an exclusion criterion for study entry given the intense nature of the protocol regarding blood draws, apheresis, biopsies and FDG-PET/CT imaging.
Inadequate venous access for phlebotomy and apheresis procedures as assessed by the study team.
Women who are breastfeeding.
A life-threatening underlying illness that according to the study team requires immediate intervention such as PML requiring initiation of ARVs or lymphomas requiring chemotherapy initiation.
An inability to consent that is estimated by the study team to be irreversible.
History of significant medical non-adherence which would, in the opinion of the investigator, interfere with study participation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bethesda?

Yes, this clinical trial (NCT02147405) has an active research site in Bethesda, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Immune Reconstitution Inflammatory Syndrome Treatment Options in Bethesda, MD

If you're searching for immune reconstitution inflammatory syndrome treatment options in Bethesda, MD, this clinical trial (NCT02147405) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bethesda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced immune reconstitution inflammatory syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all immune reconstitution inflammatory syndrome clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Bethesda, MD

See all multiple myeloma clinical trials recruiting in Bethesda — not just this study.

Browse Multiple Myeloma Trials in Bethesda →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsUTI TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Bethesda?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Bethesda, MD